Conduction system disease in cardiac amyloidosis

Area of Science:

• Cardiology
• Electrophysiology
• Cardiac Electrophysiology

Background:

• Cardiac amyloidosis (CA) profoundly affects the heart's conductive system.
• Atrial fibrillation is the most frequent electrophysiological abnormality in CA, linked to increased mortality and hospitalizations.
• Thromboembolic risk is elevated in CA patients, even without atrial fibrillation, and atrioventricular nodal disease is common.

Purpose of the Study:

• To review the diverse effects of cardiac amyloidosis on the cardiac conductive system.
• To discuss the implications for arrhythmia management and therapeutic strategies.

Main Methods:

• Literature review of studies on cardiac amyloidosis and its electrophysiological manifestations.
• Analysis of data regarding atrial fibrillation, thromboembolism, and ventricular arrhythmias in CA.
• Evaluation of current and emerging treatment modalities.

Main Results:

• Atrial fibrillation is the most common manifestation, associated with poor outcomes.
• Thromboembolism risk is high, irrespective of atrial fibrillation or CHA2DS2-VASc score.
• Atrioventricular nodal disease is prevalent and may precede CA diagnosis.
• The role of implantable cardioverter defibrillators and the impact of new CA therapies on the conductive system require further investigation.

Conclusions:

• Cardiac amyloidosis presents complex challenges for cardiac electrophysiology and patient management.
• Further research is needed to clarify arrhythmia incidence, optimize device therapy, and understand the electrophysiological effects of novel CA treatments.